

# ESMO Leaders Generation Programme: an alumni insight



Leticia De Mattos Arruda,<sup>1</sup> Carmen Criscitiello,<sup>2</sup> Matteo Lambertini,<sup>3</sup> Guillem Argiles<sup>1</sup>

**To cite:** Arruda LDM, Criscitiello C, Lambertini M, *et al.* ESMO Leaders Generation Programme: an alumni insight. *ESMO Open* 2018;3:e000312. doi:10.1136/esmoopen-2017-000312

Received 13 December 2017  
Accepted 13 December 2017

<sup>1</sup>Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain  
<sup>2</sup>Division of Early Drug Development, European Institute of Oncology, Milano, Italy  
<sup>3</sup>Department of Medicine, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium

**Correspondence to**  
Dr Guillem Argiles; gargiles@vhio.net

[Click here to listen to the Podcast](#)

Several alumni of the European Society for Medical Oncology (ESMO) Leaders Generation Programme introduce the scope, aims and goals of the programme. The ESMO Leaders Generation Programme was designed to shape the future of the oncology profession as well as the future of ESMO. This exciting and intensive course has been specifically created for young oncologists to provide them with specific training needed for future leadership. Covered topics include ESMO and the world of oncology as well as the development of personal skills especially in the areas of communication, leadership and career development. All qualified medical or clinical oncologists working in Europe who are ESMO members and aged between 31 years and 45 years are invited to apply for the programme. The course is divided into

two parts and provides a variety of interactive training as well as mentoring by experts in the field of oncology. Applications can be filled out on the ESMO home page. The alumni give detailed insights on their most valuable ESMO Leaders Generation Programme experience and encourage applying to the programme.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.